PBAC's latest decision on Sitagliptin with simvastatin: Recommended with restriction (2012). Considered for For use in patients with type 2 diabetes who are currently receiving treatment with simvastatin and who satisfy the criteria for prescribing DPP-4 inhibitors.
PBAC outcome
Recommended with restriction
Authority Required (Streamlined)
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2012
Submissions
1
2012 → 2012
Eligible population
patients with type 2 diabetes who are currently receiving treatment with simvastatin and who satisfy the criteria for prescribing DPP-4 inhibitors
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
RCT
Key trials
P255, P153
Comparator
sitagliptin and simvastatin taken concomitantly
Economic model
Cost-minimisation
Budget impact
$10M
ICER note
Cost-minimisation analysis; no ICER calculated as products are bioequivalent